Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
Ccnd1
REST API REST API
Rattus norvegicus
Ccnd1 is differentially expressed in 106 experiments: 72 organism parts: hippocampus, frontal cortex, ... (70 more);, 8 disease states: normal, diabetes mellitus, ... (6 more);, 14 cell types 2 cell lines 26 compound treatments and 21 other conditions.
Orthologs F1NS84_CHICK (Gallus gallus)   Ccnd1 (Mus musculus)   F6S8K9_CIOIN (Ciona intestinalis)   CCND1 (Homo sapiens)   ccnd1 (Danio rerio)   CycD (Drosophila melanogaster)   ccnd1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term cell division, cyclin-dependent protein kinase regulator activity, regulation of phosphorylation, protein binding, cytoplasm, intracellular, regulation of catalytic activity, positive regulation of cell proliferation, membrane, regulation of cyclin-dependent protein kinase activity, negative regulation of Wnt receptor signaling pathway, cell cycle, Wnt receptor signaling pathway, regulation of cell cycle, protein kinase binding, G1/S transition of mitotic cell cycle, nucleus, canonical Wnt receptor signaling pathway, kinase activity, response to drug, response to DNA damage stimulus, response to X-ray, endoplasmic reticulum unfolded protein response, response to ethanol, enzyme binding, protein kinase activity, response to corticosterone stimulus, mammary gland epithelial cell proliferation, response to magnesium ion, response to vitamin E, response to organic nitrogen, lactation, response to iron ion, response to calcium ion, positive regulation of mammary gland epithelial cell proliferation, fat cell differentiation, response to UV-A, re-entry into mitotic cell cycle, response to estrogen stimulus, organ regeneration, positive regulation of cyclin-dependent protein kinase activity, liver development, response to organic substance, negative regulation of epithelial cell differentiation, mammary gland alveolus development, cyclin-dependent protein kinase holoenzyme complex, response to steroid hormone stimulus, cellular response to organic substance, response to glucocorticoid stimulus, Leydig cell differentiation, protein phosphorylation, positive regulation of protein phosphorylation, mitotic cell cycle G1/S transition DNA damage checkpoint, response to organic cyclic compound
InterPro Term Cyclin-like, Cyclin_N, Cyclin_C, Cyclin_A/B/D/E
UniProt Accession Q1RP72, Q1JUA4, Q99NB4, P39948
Search EB-eye ENSRNOG00000020918
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-3309, E-AFMX-7, E-GEOD-464, E-GEOD-16981, E-GEOD-2870, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-20037

Factor Value U/D Experiments
Rat-1 fibroblast cell line 15.19
1
E-GEOD-20037
Rat-1 fibroblast cell line TGR
1
E-GEOD-20037


Cell type

studied in E-GEOD-5940, E-MEXP-31, E-GEOD-830, E-GEOD-1567, E-TABM-130, ... (7 experiments)

Factor Value U/D Experiments
granule cell
1
1
E-GEOD-1994
spermatide
1
E-MEXP-31
fibroblast
1
1
E-GEOD-2032
myoctye
1
1
E-GEOD-2032
alveolar epithelial type II
1
E-GEOD-1567
spermatogonium
1
E-TABM-130
8 more value(s).


Disease state

studied in E-GEOD-1872, E-GEOD-2470, E-GEOD-594, E-GEOD-464, E-GEOD-4745, ... (7 experiments)

Factor Value U/D Experiments
diabetes mellitus
5
2
E-GEOD-2470, E-GEOD-4745
Sham
1
E-MEXP-2583
bladder carcinoma
1
E-MTAB-104
moderate spinal cord injury
1
E-GEOD-464
BDL 7 days
1
E-MEXP-2583
bone fracture
1
E-GEOD-594
2 more value(s).


Compound treatment

studied in E-GEOD-4959, E-GEOD-5509, E-GEOD-1888, E-MEXP-2098, E-MEXP-1169, ... (12 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-2303, E-MEXP-2098, E-GEOD-4745, E-GEOD-3173, E-GEOD-1888 ... (5 experiments)
control
2
E-GEOD-4959, E-GEOD-6119
sulphated cholecystokinin-8
1
E-MEXP-1169
pregnenolone 16alpha-carbonitrile
1
E-GEOD-4959
butyrate
1
E-GEOD-424
clofibrate
1
E-GEOD-2303
20 more value(s).


Cellular component

studied in E-GEOD-15737

Factor Value U/D Experiments
neuromuscular junction
1
E-GEOD-15737
non-neuromuscular junction
1
E-GEOD-15737


Clinical treatment
studied in E-MEXP-976, E-GEOD-5509, E-GEOD-7002, E-GEOD-738, E-GEOD-1685, ... (7 experiments)

Cohort
studied in E-GEOD-20388

compound_treatment_design
studied in E-TABM-12

Day
studied in E-GEOD-20659

Developmental stage
studied in E-GEOD-4236, E-GEOD-13793, E-MEXP-570, E-GEOD-903, E-GEOD-20245 ... (5 experiments)

Diet
studied in E-GEOD-21681

Fluidics machine
studied in E-TABM-536

Genetic modification
studied in E-GEOD-6428

Genotype
studied in E-GEOD-20037, E-MTAB-323, E-GEOD-20214

Growth condition
studied in E-MEXP-2863, E-GEOD-7501, E-GEOD-6102, E-GEOD-20659, E-MEXP-532, ... (7 experiments)

Individual
studied in E-TABM-536

Injury
studied in E-GEOD-1371, E-GEOD-1685

Material type
studied in E-GEOD-4192, E-GEOD-467, E-MEXP-2527

Phenotype
studied in E-MIMR-541, E-GEOD-2275

protocol
studied in E-GEOD-20895

Protocol type
studied in E-GEOD-691, E-GEOD-1616, E-MEXP-1565

Replicate
studied in E-GEOD-4192

Strain or line
studied in E-MEXP-776, E-MTAB-322, E-TABM-457, E-TABM-418, E-GEOD-20388, ... (8 experiments)

Test result
studied in E-GEOD-4745

Treatment
studied in E-GEOD-16981, E-GEOD-19909

Processing time: 0.104 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM